Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
about
HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in São Paulo, BrazilNatural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in ChinaNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Hepatitis C virus NS3 mutations in haemophiliacsNationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran.Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor ResistanceNaturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C.Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy.CD36 is a co-receptor for hepatitis C virus E1 protein attachment.Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal studyve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogensHepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.West Nile virus drug discovery.Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Safety of direct antiviral agents in the management of hepatitis C.Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold.Hepatitis C virus resistance to the new direct-acting antivirals.A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System.No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy.Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection.Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing SimeprevirMolecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China.Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus
P2860
Q28538943-0E788282-25DA-450E-85DE-9577B3E2D364Q28552134-801C9B84-841E-4E9B-A6B4-1A4DD6C43521Q33672648-CCB7C543-57B1-416A-8A6D-3669E757BD73Q34111759-1FB8227A-BC40-47A9-9584-1A1443DEDE14Q34599453-256A6033-D856-4C35-8813-956A2E1DB307Q35061753-C7ED684A-0907-40D0-B781-584A814E8856Q35100139-DD2CE3A3-5C0F-4C5D-9A84-089ABEBBA53BQ35757761-9DE65199-8CEA-44C4-8A57-510B925AFE9CQ35917596-9585133F-BACB-4833-A755-C682E6007C85Q36278496-6528CB1A-DDEB-4598-872B-873F3A69B8BAQ36290778-317DF8E8-B272-489F-B73F-3BF16D2E45F9Q36292486-8A9F0FE7-D016-4D4D-BAC4-5AE86CE6EBF7Q36299928-8FD70493-D20C-4886-9EAF-AC9473F89DF5Q36602246-A580EC2A-760F-4615-A961-F5052DCAF68CQ36689877-A8DFCC10-6590-46BF-8DD4-9B760FEE8F97Q36766590-E732213F-A69A-414E-B93A-3A60019AE5F0Q36933403-63FFD281-4924-4CC3-8D66-E541DC1EE387Q37426527-A29FBC98-917D-4653-8E09-2DB92929DC3DQ37666750-585B340E-EE31-493C-AACF-46D04E1CF6F3Q38193551-AA1FA7FB-B9AB-45E0-B137-0867DBC5F4EEQ38533619-6482828A-5E70-429B-87C5-808B3201470DQ38818416-8F1C6053-FE14-4D6B-ACE6-E4CD99535C44Q38885160-CF61CC95-E40D-4A0D-8281-4D100F088EADQ38887954-1FF0075F-63A2-432C-BCE1-5B01BFBD5058Q40042032-68793070-13AA-4B7B-A4B4-1CEFA8A363E9Q40868771-E2DA56E8-BA61-4832-9E66-FD3C5B7BD1DDQ41007229-107454F0-F142-4CA0-A4BA-96D00996BA3AQ41127462-F204242B-F7F8-41CD-B2B4-1098C85DBC00Q41259954-0732099D-E598-4C1F-ACD3-D74E199A9161Q41666553-04A6F0D7-05FF-4432-A0CE-BFFD8532E5A4Q41907710-4901BAAB-C1E4-4D0B-85FB-9324ACDA3EA0Q42205040-2B54094A-C1E6-43F2-9E69-36512A611869Q45324124-BE816273-C92F-4435-A95E-D6E43800A4D5Q47121746-BD90D59B-CE65-41EA-A74C-22DA435F70B8Q59126211-809D4D7B-0ADE-43E0-ADE5-8F8FAA40F8F8
P2860
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
@ast
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
@en
type
label
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
@ast
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
@en
prefLabel
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
@ast
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
@en
P2093
P2860
P356
P1433
P1476
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
@en
P2093
Antonio Piralla
Giorgio Barbarini
Loretta Fiorina
Luca Dossena
Marta Gatti
Roberto Gulminetti
Stefania Paolucci
Stefano Novati
P2860
P356
10.1186/1743-422X-9-245
P577
2012-10-24T00:00:00Z